FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Carisoprodol Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Carisoprodol Tablets USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.
Carisoprodol Tablets USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see Dosage and Administration (2)].
History
There is currently no drug history available for this drug.
Other Information
Carisoprodol Tablets USP are available as 350 mg round, white tablets for oral administration. Carisoprodol is a white, crystalline powder, having a mild, characteristic odor and a bitter taste. It is slightly soluble in water; freely soluble in alcohol, in chloroform, and in acetone; and its solubility is practically independent of pH. Carisoprodol is present as a racemic mixture. Chemically, carisoprodol is N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate and the molecular formula is C12H24N2O4, with a molecular weight of 260.33. The structural formula is:
Other ingredients in Carisoprodol Tablets, USP include croscarmellose sodium, hydrogenated vegetable oil, hypromellose, magnesium stearate and microcrystalline cellulose.
Sources
Carisoprodol Manufacturers
- Proficient Rx Lp
- Preferred Pharmaceuticals, Inc.
- Bionpharma Inc.
- Blenheim Pharmacal, Inc.
- Blenheim Pharmacal, Inc.
- Blenheim Pharmacal, Inc.
- A-s Medication Solutions Llc
- A-s Medication Solutions Llc
- Rebel Distributors Corp.
Carisoprodol | Rebel Distributors Corp.
The recommended dose of Carisoprodol is 350 mg three times a day and at bedtime. The recommended maximum duration of Carisiprodol use is up to two or three weeks
The recommended dose of Carisoprodol Tablets, USP is 350 mg three times a day and at bedtime. The recommended maximum duration of Carisoprodol Tablets, USP use is up to two or three weeks.
- Altura Pharmaceuticals, Inc.
- Stat Rx Usa Llc
- West-ward Pharmaceutical Corp
- Keltman Pharmaceuticals Inc.
- Redpharm Drug Inc.
- Pd-rx Pharmaceuticals, Inc.
- Rising Pharmaceuticals, Inc.
- Stat Rx Usa Llc
- Life Line Home Care Services, Inc
- Physicians Total Care, Inc.
- Avkare, Inc.
- Mylan Institutional Inc.
- Sun Pharmaceutical Industries Limited
- Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
- Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
- Rising Pharmaceuticals, Inc.
Carisoprodol | Rising Pharmaceuticals, Inc.
The recommended dose of Carisoprodol, Aspirin and Codeine Phosphate tablets, is 1 or 2 tablets, four times daily in adults. One Carisoprodol, Aspirin and Codeine Phosphate tablet contains 200 mg of Carisoprodol, 325 mg of Aspirin and 16 mg of Codeine Phosphate. The maximum daily dose (i.e., two tablets taken four times daily) will provide 1600 mg of carisoprodol, 2600 mg of aspirin and 128 mg of codeine phosphate per day. The recommended maximum duration of Carisoprodol, Aspirin and Codeine Phosphate tablets use is up to two or three weeks.
- Mirror Pharmaceuticals Llc
Carisoprodol | Mirror Pharmaceuticals Llc
The recommended dose of Carisoprodol, Aspirin and Codeine Phosphate tablets, is 1 or 2 tablets, four times daily in adults. One Carisoprodol, Aspirin and Codeine Phosphate tablet contains 200 mg of Carisoprodol, 325 mg of Aspirin and 16 mg of Codeine Phosphate. The maximum daily dose (i.e., two tablets taken four times daily) will provide 1600 mg of carisoprodol, 2600 mg of aspirin and 128 mg of codeine phosphate per day. The recommended maximum duration of Carisoprodol, Aspirin and Codeine Phosphate tablets use is up to two or three weeks.
- Aidarex Pharmaceuticals Llc
- Unit Dose Services
Carisoprodol | Bayer Healthcare Pharmaceuticals Inc.
Skyla contains 13.5 mg of levonorgestrel (LNG) released in vivo at a rate of approximately 14 mcg/day after 24 days. This rate decreases progressively to 5 mcg/day after 3 years. The average in vivo release rate of LNG is approximately 6 mcg/day over a period of 3 years.
Skyla must be removed by the end of the third year and can be replaced at the time of removal with a new Skyla if continued contraceptive protection is desired.
Skyla is supplied within an inserter in a sterile package (see Figure 1) that must not be opened until required for insertion [see Description (11)]. Do not use if the seal of the sterile package is broken or appears compromised. Use strict aseptic techniques throughout the insertion procedure [see Warnings and Precautions (5.3)].
2.1. Insertion Instructions • A complete medical and social history should be obtained to determine conditions that might influence the selection of a levonorgestrel-releasing intrauterine system (LNG IUS) for contraception . If indicated, perform a physical examination, and appropriate tests for any forms of genital or other sexually transmitted infections. [See Contraindications (4) and Warnings and Precautions (5.10).] • Follow the insertion instructions exactly as described in order to ensure proper placement and avoid premature release of Skyla from the inserter. Once released, Skyla cannot be re-loaded. • Skyla should be inserted by a trained healthcare provider. Healthcare providers should become thoroughly familiar with the insertion instructions before attempting insertion of Skyla. • Insertion may be associated with some pain and/or bleeding or vasovagal reactions (for example, syncope, bradycardia) or seizure in an epileptic patient, especially in patients with a predisposition to these conditions. Consider administering analgesics prior to insertion. Timing of Insertion • Insert Skyla into the uterine cavity during the first seven days of the menstrual cycle or immediately after a first trimester abortion. Back up contraception is not needed when Skyla is inserted as directed. • Postpone postpartum insertion and insertions following second trimester abortions a minimum of six weeks or until the uterus is fully involuted. If involution is delayed, wait until involution is complete before insertion [see Warnings and Precautions (5.6, 5.7)]. Tools for Insertion Preparation • Gloves • Speculum • Sterile uterine sound • Sterile tenaculum • Antiseptic solution, applicator Procedure • Sterile gloves • Skyla with inserter in sealed package • Instruments and anesthesia for paracervical block, if anticipated • Consider having an unopened backup Skyla available • Sterile, sharp curved scissors Preparation for insertion • Exclude pregnancy and confirm that there are no other contraindications to the use of Skyla. • Ensure that the patient understands the contents of the Patient Information Booklet and obtain the signed patient informed consent located on the last page of the Patient Information Booklet. • With the patient comfortably in lithotomy position, do a bimanual exam to establish the size, shape and position of the uterus. • Gently insert a speculum to visualize the cervix. • Thoroughly cleanse the cervix and vagina with a suitable antiseptic solution. • Prepare to sound the uterine cavity. Grasp the upper lip of the cervix with a tenaculum forceps and gently apply traction to stabilize and align the cervical canal with the uterine cavity. Perform a paracervical block if needed. If the uterus is retroverted, it may be more appropriate to grasp the lower lip of the cervix. The tenaculum should remain in position and gentle traction on the cervix should be maintained throughout the insertion procedure. • Gently insert a uterine sound to check the patency of the cervix, measure the depth of the uterine cavity in centimeters, confirm cavity direction, and detect the presence of any uterine anomaly. If you encounter difficulty or cervical stenosis, use dilatation, and not force, to overcome resistance. If cervical dilatation is required, consider using a paracervical block. Insertion ProcedureProceed with insertion only after completing the above steps and ascertaining that the patient is appropriate for Skyla. Ensure use of aseptic technique throughout the entire procedure.
Step 1–Opening of the package • Open the package (Figure 1). The contents of the package are sterile.Figure 1: Opening the Skyla Package
• Using sterile gloves, lift the handle of the sterile inserter and remove from the sterile package. Step 2–Load Skyla into the insertion tube • Push the slider forward as far as possible in the direction of the arrow thereby moving the insertion tube over the Skyla T-body to load Skyla into the insertion tube (Figure 2). The tips of the arms will meet to form a rounded end that extends slightly beyond the insertion tube.Figure 2: Move slider all the way to the forward position to load Skyla
• Maintain forward pressure with your thumb or forefinger on the slider . DO NOT move the slider downward at this time as this may prematurely release the threads of Skyla. Once the slider is moved below the mark, Skyla cannot be re-loaded . Step 3–Setting the Flange • Holding the slider in this forward position, set the upper edge of the flange to correspond to the uterine depth (in centimeters) measured during sounding (Figure 3).Figure 3: Setting the flange
Figure 3: Setting the flange
Step 4–Skyla is now ready to be inserted • Continue holding the slider in this forward position. Advance the inserter through the cervix until the flange is approximately 1.5–2 cm from the cervix and then pause (Figure 4).Figure 4: Advancing insertion tube until flange is 1.5 to 2 cm from the cervix
Do not force the inserter. If necessary, dilate the cervical canal.
Step 5–Open the arms • While holding the inserter steady, move the slider down to the mark to release the arms of Skyla (Figure 5). Wait 10 seconds for the horizontal arms to open completely.Figure 5: Move the slider back to the mark to release and open the arms
Step 6–Advance to fundal positionAdvance the inserter gently towards the fundus of the uterus until the flange touches the cervix. If you encounter fundal resistance do not continue to advance. Skyla is now in the fundal position (Figure 6). Fundal positioning of Skyla is important to prevent expulsion.
Figure 6: Move Skyla into the fundal position
Figure 6. Move Skyla into the fundal position
Step 7–Release Skyla and withdraw the inserter • Holding the entire inserter firmly in place, release Skyla by moving the slider all the way down (Figure 7).Figure 7: Move the slider all the way down to release Skyla from the insertion tube
• Continue to hold the slider all the way down while you slowly and gently withdraw the inserter from the uterus. • Using a sharp, curved scissor, cut the threads perpendicular, leaving about 3 cm visible outside of the cervix [cutting threads at an angle may leave sharp ends (Figure 8)]. Do not apply tension or pull on the threads when cutting to prevent displacing Skyla..
Figure 8: Cutting the threads
Skyla insertion is now complete. Prescribe analgesics, if indicated. Keep a copy of the Consent Form with lot number for your records. Important information to consider during or after insertion • If you suspect that Skyla is not in the correct position, check placement (for example, using transvaginal ultrasound). Remove Skyla if it is not positioned completely within the uterus. A removed Skyla must not be re-inserted. • If there is clinical concern, exceptional pain or bleeding during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound. 2.2 Patient Follow-up • Patients should be reexamined and evaluated 4 to 6 weeks after insertion and once a year thereafter, or more frequently if clinically indicated. 2.3 Removal of Skyla Timing of Removal • Skyla should not remain in the uterus after 3 years. • If pregnancy is not desired, the removal should be carried out during menstruation, provided the woman is still experiencing regular menses. If removal will occur at other times during the cycle, consider starting a new contraceptive method a week prior to removal. If removal occurs at other times during the cycle and the woman has had intercourse in the week prior to removal, she is at risk of pregnancy. [See Dosage and Administration (2.4).] Tools for Removal Preparation • Gloves • Speculum Procedure • Sterile forceps Removal Procedure • Remove Skyla by applying gentle traction on the threads with forceps (Figure 9).Figure 9: Removal of Skyla
• If the threads are not visible, determine location of Skyla by ultrasound [see Warnings and Precautions (5.10)]. • If Skyla is found to be in the uterine cavity on ultrasound exam, it may be removed using a narrow forceps, such as an alligator forceps. This may require dilation of the cervical canal. After removal of Skyla, the system should be examined to ensure that it is intact. • Removal may be associated with some pain and/or bleeding or vasovagal reactions (for example, syncope, or a seizure in an epileptic patient). 2.4 Continuation of Contraception after Removal • If pregnancy is not desired and if a woman wishes to continue using Skyla, a new system can be inserted immediately after removal any time during the cycle. • If a patient with regular cycles wants to start a different birth control method, time removal and initiation of new method to ensure continuous contraception. Either remove Skyla during the first 7 days of the menstrual cycle and start the new method or start the new method at least 7 days prior to removing Skyla if removal is to occur at other times during the cycle. • If a patient with irregular cycles or amenorrhea wants to start a different birth control method, start the new method at least 7 days before removal. - Mirror Pharmaceuticals Llc
- H.j. Harkins Company, Inc.
- Pd-rx Pharmaceuticals, Inc.
- Bryant Ranch Prepack
- Wallace Pharmaceuticals Inc.
- Cardinal Health
- Remedyrepack Inc.
- Remedyrepack Inc.
- A-s Medication Solutions Llc
- A-s Medication Solutions Llc
- Eon Labs, Inc.
Carisoprodol | Eon Labs, Inc.
The recommended daily dose of Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP is 1 or 2 tablets, four times daily in adults. One Carisoprodol, Aspirin and Codeine Phosphate Tablet, USP contains 200 mg of carisoprodol, 325 mg of aspirin, and 16 mg of codeine phosphate. The maximum daily dose (i.e., two tablets taken four times daily) will provide 1600 mg of carisoprodol, 2600 mg of aspirin, and 128 mg of codeine phosphate per day. The recommended maximum duration of Carisoprodol, Aspirin and Codeine Phosphate Tablet, USP use is up to two or three weeks.
- Lake Erie Medical Dba Quality Care Products Llc
- Dispensing Solutions, Inc.
- Dispensing Solutions, Inc.
- Watson Laboratories, Inc.
- Aurobindo Pharma Limited
- Apotheca, Inc.
- Qualitest Pharmaceuticals
- American Health Packaging
Carisoprodol | Menper Distributors, Inc
Directions
do not use more than doses in any 24-hour period repeat every 4 hours choose dosage by weight (if weight is not known, choose by age) measure with the dosing device provided. Do not use with any other device.Age Weight Dose
2 to under 6 years 24-47 Lbs 1 mL
under 2 years under 24 Lbs ask as doctor
- Mckesson Packaging Services A Business Unit Of Mckesson Corporation
- Sciegen Pharmaceuticals, Inc.
Carisoprodol | Aspen Veterinary Resources
DOSAGE AND ADMINISTRATION:
For arthritis or mycoplasma pneumonia - 5 mg per pound of body weight intramuscularly once daily for three to seven days as needed. One mL per 60 lb body weight will provide 5 mg/lb.
For optimal results, initiate treatment as soon as possible.
As with any multi-dose vial, practice aseptic techniques in withdrawing each dose.
Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.
Each mL contains:
Lincomycin hydrochloride equivalent to lincomycin 300 mg; also benzyl alcohol 9.45 mg added as a preservative.
- Mutual Pharmaceutical Company, Inc.
- Direct Rx
Carisoprodol | Kroger Company
• this product does not contain directions or complete warnings for adult use • do not give more than directed (see overdose warning) • shake well before using • mL = milliliter; tsp = teaspoonful • find right dose on chart. If possible, use weight to dose; otherwise, use age. • remove the child protective cap and squeeze your child’s dose into the dosing cup • repeat dose every 4 hours while symptoms last • do not give more than 5 times in 24 hoursWeight (lb)
Age (yr)
Dose (mL or tsp)*
under 24
under 2 years
ask a doctor
24-35
2-3 years
5 mL (1 tsp)
36-47
4-5 years
7.5 mL (1 1/2 tsp)
48-59
6-8 years
10 mL (2 tsp)
60-71
9-10 years
12.5 mL (2 1/2 tsp)
72-95
11 years
15 mL (3 tsp)
*or as directed by a doctor
Attention: use only enclosed dosing cup specifically designed for use with this product. Do not use any other dosing device.
- Golden State Medical Supply, Inc.
- Aphena Pharma Solutions – Tennessee, Llc
- Cardinal Health
- Bryant Ranch Prepack
- Northwind Pharmaceuticals
- Proficient Rx Lp
- Vensun Pharmaceuticals, Inc.
- Bryant Ranch Prepack
- West-ward Pharmaceutical Corp
- Preferred Pharmaceuticals, Inc.
Login To Your Free Account